

立法會
Legislative Council

LC Paper No. LS4/04-05

**Paper for the House Committee Meeting
on 15 October 2004**

**Legal Service Division Report on
Proposed Resolution under section 29 of the
Pharmacy and Poisons Ordinance (Cap. 138)**

The Secretary for Health, Welfare and Food ("the Secretary") has given notice to move a motion at the Council meeting on 20 October 2004. The motion seeks the Legislative Council's approval of the Pharmacy and Poisons (Amendment) (No.3) Regulation 2004 and the Poisons List (Amendment) (No.3) Regulation 2004, both made by the Pharmacy and Poisons Board ("the Board") pursuant to section 29 of the Pharmacy and Poisons Ordinance (Cap. 138).

2. According to the draft speech of the Secretary, the Pharmacy and Poisons (Amendment) (No. 3) Regulation 2004 and the Poisons List (Amendment) (No. 3) Regulation 2004 seek to add 4 new drugs/medicines, i.e. Articaine and its salts, Atazanavir and its salts, Efalizumab and Pemirolast and its salts to part A of the First and Third Schedules to the Pharmacy and Poisons Regulations and part A of Part I of the Poisons List. The Secretary has provided, in addition to his draft speech, supplementary information on these 4 new drugs/medicines, which is attached for Members' reference (see Annex). Their addition means that pharmaceutical products containing any of these 4 substances must be sold in pharmacies by or under the supervision of a registered pharmacist and in his presence, with the support of prescriptions given by a registered medical practitioner, registered dentist or registered veterinary surgeon.

3. The Board considers that the proposed amendments necessary in view of the potency, toxicity and potential side-effects of the medicines concerned.

4. The two Amendment Regulations shall come into operation on the day when they are published in the Gazette after being approved by the Legislative Council.

5. The Panel on Health Services has not been consulted on the two Amendment Regulations.

6. The two Amendment Regulations are in order from the legal point of view.

Encl

Prepared by

LAI Shun-wo, Monna
Assistant Legal Adviser
Legislative Council Secretariat
11 October 2004

Poisons List (Amendment) (No. 3) Regulation 2004

Pharmacy and Poisons (Amendment) (No. 3) Regulation 2004

Supplementary Information to the Legislative Council

〈 2004年毒藥表 (修訂) (第3號) 規例 〉
〈 2004年藥劑業及毒藥 (修訂) (第3號) 規例 〉
提交立法會的補充資料

Drug Name 藥名	Proposed Classification 建議類別	Reason 原因
Articaine; its salts (阿替卡因; 其鹽類)	Part I, First and Third Schedules poison 第一部附表一及附表三毒藥	This drug is used as a local (infiltration and nerve block) anaesthetic for dental procedures. It should only be used for this purpose and when the need is established by a dental practitioner. 此藥用作牙科手術局部 (浸潤及神經傳導阻滯) 麻醉劑。此藥應該只用於此用途及經牙醫診斷有需要時才使用。

Drug Name 藥名	Proposed Classification 建議類別	Reason 原因
Atazanavir; its salts (阿扎那韋; 其鹽類)	Part I, First and Third Schedules poison 第一部附表一及附表三毒藥	<p>This drug is used to treat HIV-1/AIDS infection in combination with other anti-HIV medications. A doctor's decision is required as to whether or not this medicine should be used after proper diagnosis. Medical monitoring is also required during administration.</p> <p>此藥用於與其它藥物一起治療HIV-1/愛滋病感染。此藥需經醫生確診後，決定有需要時才使用。用此藥時亦需要醫生小心觀察病人。</p>
Efalizumab (依法珠單抗)	Part I, First and Third Schedules poison 第一部附表一及附表三毒藥	<p>This drug is used to treat moderate to severe plaque psoriasis in adults. Use of this drug requires proper medical diagnosis and careful monitoring of its side effects.</p> <p>此藥用於治療成人之中度至嚴重性版狀牛皮癬。用此藥時需要經醫生確診及小心觀察病人有否產生副作用。</p>

Drug Name 藥名	Proposed Classification 建議類別	Reason 原因
Pemirolast; its salts (吡嘧司特; 其鹽類)	Part I, First and Third Schedules poison 第一部附表一及附表三 毒藥	<p data-bbox="906 300 1479 477">This drug is used to treat allergic conjunctivitis and spring catarrh. Its use requires careful monitoring of its side effects by a doctor.</p> <p data-bbox="906 577 1479 712">此藥用於治療敏感性結膜炎及春季結膜炎。用此藥時需由醫生小心觀察病人有否產生副作用。</p>